These data are consistent with those obtained in HER2-related breast cancer preclinical models [17], where p140Cap limits the aggressiveness of HER2-related tumors, increasing both sensitivity to apoptosis and tumor differentiation. This evidence concerns the gene ERBB2 and breast carcinoma.